Drugs / ADCT-901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04972981 | Sep 2021 → Sep 2024 | cancer | ADC Therapeutics S.A. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-27 | ADC Therapeutics S.A. | ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors adctherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADCT-901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04972981 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT04972981 ↗ |